This study is investigating if low-dose naltrexone (LDN) can help reduce pain for people with painful diabetic neuropathy (nerve damage caused by diabetes). You might be able to join if you are over 18, have had painful diabetic neuropathy for more than six months, and have not found relief from at least one other standard treatment. The study will compare naltrexone to a placebo (an inactive pill) to see if it improves your pain and how much it affects your daily activities. The study is currently unclear about its recruitment status and plans to enroll 35 participants.

Study design

This is a randomized, double-blind, placebo-controlled, crossover study. This means you will be randomly assigned to receive either naltrexone or a placebo first, and then switch to the other treatment, without you or your doctors knowing which you are taking at any given time.

What's involved

You will receive either naltrexone or a placebo for 8 weeks and 4 weeks, respectively, with no break in between. The study measures changes in your pain and disability from when you start until week 12.

Compensation

Not stated in the trial record.

Follow-up

Your pain and disability will be measured from when you enroll through week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.